TABLE 2:

Results of proton MR spectroscopy in parieto-occipital white matter and gray matter

A: Patients’ last investigations
Patient	No. of Studies	Age Range, year	White Matter Lipid Peak, au	White Matter Metabolites, mmol/L
Patient	No. of Studies	Age Range, year	White Matter Lipid Peak, au	t-NAA	Cr	Cho	Ins	Glx
1	3	0.8–1	5.7	9.5	4.9	2.3	3.0	11.6
2	5	0.4–4	3.0	9.5	4.7	1.5	4.6	9.8
3	2	3–5	27.8	11.1	5.4	2.4	8.1	10.5
4	1	8	23.4	11.1	6.0	2.1	5.3	13.6
5	1	8	11.2	8.5	4.8	2.0	4.0	8.6
6	2	5–9	15.5	10.1	6.1	1.8	5.1	13.4
7	2	6–9	1.9	11.3	6.1	2.1	5.8	11.3
8	1	9	21.3	9.3	5.8	2.4	6.6	10.6
9	4	7–10	11.5	11.4	5.2	1.9	4.0	14.3
10	1	10	Present	—	—	—	—	—
11	1	13	11.2	9.4	4.7	1.8	5.9	8.7
12	3	11–14	13.6	9.9	6.3	2.1	6.0	13.0
13	4	12–16	19.8	11.9	6.0	2.0	6.3	10.2
14	2	17–17	20.3	10.5	6.6	1.8	6.7	16.0
15	3	15–17	8.6	12.7	6.8	1.9	5.4	15.3
16	2	21–21	6.9	11.0	7.6	2.4	5.5	14.5
18	1	45	1.6	8.9	6.0	1.8	3.6	9.8

B: Group means and standard deviations
Group	Lipid Peak, au	Metabolites, mmol/L
Group	Lipid Peak, au	t-NAA	Cr	Cho	Ins	Glx
White matter
Patients (n = 16)	12.7 (8.1)^*	10.4 (1.2)	5.8 (0.8)^†	2.0 (0.3)^‡	5.4 (1.3)^§	12.0 (2.4)
Control subjects (n = 9)	0.6 (0.6)	9.6 (0.9)	5.1 (0.3)	1.7 (0.3)	3.5 (1.0)	12.4 (0.9)
Gray matter
Patients (n = 15)	0.9 (0.8)	11.2 (1.6)	7.1 (1.0)	1.5 (0.3)	3.9 (1.6)	17.0 (2.7)
Control subjects (n = 9)	1.1 (0.8)	11.1 (0.5)	6.5 (0.5)	1.4 (0.1)	4.3 (0.8)	15.6 (2.0)

Note.—au = arbitrary units, t-NAA = total NAA (N-acetylaspartate and N-acetylaspartylglutamate), Cr = creatine and creatine phosphate, Cho = free choline and the choline-containing compounds phosphocholine and glycerophosphorylcholine, Ins = myo-inositol, Glx = glutamine and glutamate, dashes = no data available. P values are given when P < .05 for SLS patients compared with healthy control subjects (unpaired two-tailed t test).
* P = .0002.
† P = .02.
‡ P = .005.
§ P = .001.